No Data
No Data
Oruka Therapeutics's ORKA-001: Promising Psoriasis Treatment Drives Buy Rating With 12-Month Price Target of $45
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
Express News | Oruka Therapeutics Inc - Enters License Agreement With Paragon for Worldwide Rights to Orka-001
Express News | Oruka Therapeutics: On Track to Initiate Proof-of-Concept Study in Psoriasis H2 2025, Initial Efficacy Data Expected in H2 2026
Express News | Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of Orka-001, Its Novel Half-Life Extended Anti-Il-23P19 Antibody
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, Its Novel Half-life Extended Anti-IL-23p19 Antibody
Unlock the Full List